Quarterly report pursuant to Section 13 or 15(d)

Business and Organization (Details)

v3.8.0.1
Business and Organization (Details)
$ / shares in Units, $ in Millions
1 Months Ended 9 Months Ended
Aug. 31, 2016
USD ($)
$ / shares
shares
Sep. 30, 2017
employee
Business Acquisition [Line Items]    
Number of sales employees | employee   400
Transition Therapeutics    
Business Acquisition [Line Items]    
Consideration transferred | $ $ 58.5  
Common Stock    
Business Acquisition [Line Items]    
Stock price per share (in dollars per share) | $ / shares $ 9.10  
Common Stock | Transition Therapeutics    
Business Acquisition [Line Items]    
Common stock received (in shares) | shares 6,431,899